The Latest Applications of Carbon-Nitride-Based Materials for Combination Treatment of Cancer
ACS Applied Materials & Interfaces · 2024
DOI: 10.1021/acsami.4c12350 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ACS Applied Materials & Interfaces, 2024. Verfasst von Xu-Feng Ning und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy and Nantong Key Laboratory of Small Molecular Drug Innovation, Nantong University, 226001, Nantong, Jiangsu, People's Republic of …. Hauptthemen laut MEDLINE: Neoplasms, Photochemotherapy, Photosensitizing Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 93 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy and Nantong Key Laboratory of Small Molecular Drug Innovation, Nantong University, 226001, Nantong, Jiangsu, People's Republic of China.
- Department of Gastroenterology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, People's Republic of China.
ORCID-Profile: Ming-Xuan Liu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Ning, X. F., Zhu, Y. Q., Sun, H., Yang, Y., & Liu, M. X. (2024). The Latest Applications of Carbon-Nitride-Based Materials for Combination Treatment of Cancer. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.4c12350
Vancouver
Ning XF, Zhu YQ, Sun H, Yang Y, Liu MX. The Latest Applications of Carbon-Nitride-Based Materials for Combination Treatment of Cancer. ACS Applied Materials & Interfaces. 2024. doi:10.1021/acsami.4c12350
BibTeX
@article{Ning2024,
author = {Ning, Xu-Feng and Zhu, Ya-Qi and Sun, Hao and Yang, Yuan and Liu, Ming-Xuan},
title = {The Latest Applications of Carbon-Nitride-Based Materials for Combination Treatment of Cancer},
journal = {ACS Applied Materials & Interfaces},
year = {2024},
doi = {10.1021/acsami.4c12350}
}
EUVIMED